

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Hansoh Pharmaceutical Group Company Limited**

**翰森製藥集團有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 3692)**

### **VOLUNTARY ANNOUNCEMENT**

#### **LICENSING AGREEMENT WITH SILENCE THERAPEUTICS**

The board of directors (the “**Board**”) of Hansoh Pharmaceutical Group Company Limited (the “**Company**”) and together with its subsidiaries, the “**Group**”) is pleased to announce that on October 15, 2021, the Company has entered into an exclusive license and collaboration agreement (the “**Licensing Agreement**”) with Silence Therapeutics plc (AIM: SLN and Nasdaq: SLN) (“**Silence Therapeutics**”).

Pursuant to the Licensing Agreement, the Company and Silence Therapeutics will collaborate to develop siRNAs (short interfering RNAs) for three targets leveraging Silence Therapeutics’ proprietary mRNAi GOLD™ platform. For the first two targets, the Company will have the exclusive option to license rights in China (including Hong Kong, Macau and Taiwan) (the “**Territory**”) following the completion of phase 1 studies and Silence Therapeutics will retain exclusive rights in rest of the world other than the Territory. Silence Therapeutics will be responsible for all activities up to option exercise and will retain responsibility for development outside the Territory post phase 1 studies for the first two targets. For the third target, the Company will have the exclusive option to license global rights at the point of Investigational New Drug (IND) filing. The Company will be responsible for all development activities post option exercise for the third target.

Silence Therapeutics will receive US\$16 million as an upfront payment from the Company and is eligible to receive up to US\$1.3 billion upon reaching additional development, regulatory and commercial milestones. Silence Therapeutics will also receive royalties tiered from low double-digit to mid-teens on the Company’s net product sales.

With Silence Therapeutics’ pioneering position in siRNA therapeutic development and its decades of scientific and technical experience, the Company sees substantial opportunity in Silence Therapeutics’ mRNAi GOLD™ platform to develop and bring better precision-based medicines to patients across China and worldwide.

Silence Therapeutics is a biotechnology company developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet need. Silence Therapeutics' proprietary mRNAi GOLD™ platform can be used to create siRNAs that precisely target and silence disease-associated genes in the liver. Silence Therapeutics is a company listed on the Alternative Investment Market of the London Stock Exchange (AIM: SLN) and National Association of Securities Dealers Automated Quotations stock market in the United States (Nasdaq: SLN).

To the best knowledge and belief of the Company, Silence Therapeutics is independent of the Company. Silence Therapeutics is not connected with the Company and its connected persons (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**")), save for the 0.3% shareholding held by Miss Sun Yuan, the executive director of the Company, in it. The transactions contemplated under the Licensing Agreement do not constitute any notifiable transactions or connected transactions of the Company under the Listing Rules.

By Order of the Board  
**Hansoh Pharmaceutical Group Company Limited**  
**Zhong Huijuan**  
*Chairlady*

Hong Kong, October 15, 2021

*As at the date of this announcement, the Board comprises Ms. Zhong Huijuan as chairlady and executive director, Mr. Lyu Aifeng and Miss Sun Yuan as executive directors, and Mr. Lin Guoqiang, Mr. Chan Charles Sheung Wai and Ms. Yang Dongtao as independent non-executive directors.*